OTCMKTS:ANTHAnthera Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Anthera Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.03 +0.00 (+6.30 %) (As of 06/5/2020 04:00 PM ET) Add Compare Share Today's Range$0.02Now: $0.03▼$0.0350-Day Range$0.02MA: $0.02▼$0.0352-Week Range$0.02Now: $0.03▼$0.08Volume130,189 shsAverage Volume46,182 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABeta2.07 ProfileAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license agreements with Amgen, Inc., and Eli Lilly and Company. Anthera Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Hayward, California.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Anthera Pharmaceuticals. Previous Next 2.5 Community Rank Outperform VotesAnthera Pharmaceuticals has received 337 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAnthera Pharmaceuticals has received 327 “underperform” votes. (Add your “underperform” vote.)Community SentimentAnthera Pharmaceuticals has received 50.75% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Anthera Pharmaceuticals and other stocks. Vote “Outperform” if you believe ANTH will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ANTH will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAnthera Pharmaceuticals does not currently pay a dividend.Dividend GrowthAnthera Pharmaceuticals does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Anthera Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.08% of the stock of Anthera Pharmaceuticals is held by insiders. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.50 out of 5 stars Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:ANTH Previous Symbol CUSIPN/A CIK1316175 Webwww.anthera.com Phone510-856-5600Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding SharesN/AMarket CapN/A Next Earnings DateN/A OptionableOptionable OTC:ANTH Rates by TradingView Receive ANTH News and Ratings via Email Sign-up to receive the latest news and ratings for ANTH and its competitors with MarketBeat's FREE daily newsletter. Anthera Pharmaceuticals (OTCMKTS:ANTH) Frequently Asked Questions How has Anthera Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Anthera Pharmaceuticals' stock was trading at $0.0292 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ANTH stock has decreased by 1.7% and is now trading at $0.0287. View which stocks have been most impacted by Coronavirus. How were Anthera Pharmaceuticals' earnings last quarter? Anthera Pharmaceuticals Inc (OTCMKTS:ANTH) issued its earnings results on Monday, March, 5th. The biopharmaceutical company reported ($0.73) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.82) by $0.09. View Anthera Pharmaceuticals' earnings history. When did Anthera Pharmaceuticals' stock split? How did Anthera Pharmaceuticals' stock split work? Shares of Anthera Pharmaceuticals reverse split before market open on Monday, May 1st 2017. The 1-8 reverse split was announced on Friday, April 28th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, April 28th 2017. An investor that had 100 shares of Anthera Pharmaceuticals stock prior to the reverse split would have 13 shares after the split. Has Anthera Pharmaceuticals been receiving favorable news coverage? News stories about ANTH stock have been trending extremely negative recently, according to InfoTrie Sentiment. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Anthera Pharmaceuticals earned a news impact score of -5.0 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the near term. View the latest news aboutAnthera Pharmaceuticals. Who are some of Anthera Pharmaceuticals' key competitors? Some companies that are related to Anthera Pharmaceuticals include 89bio (ETNB), Advanz Pharma (CXRXF), Aeolus Pharmaceuticals (AOLS), Affymax (AFFY), American Oriental Bioengineering (AOBI), Aoxing Pharmaceutical (AOXG), Bohai Pharmaceuticals Group (BOPH), CannTrust (CTST), Epirus Biopharmaceuticals (EPRSQ), ERBA Diagnostics (ERBA), FutureWorld (FWDG), GlobeImmune (GBIM), MOTIF BIO PLC/S (MTFB), Myrexis (MYRX) and NeuroVive Pharmaceutical (NEVPF). View all competitors. What other stocks do shareholders of Anthera Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Anthera Pharmaceuticals investors own include Ocular Therapeutix (OCUL), Synergy Pharmaceuticals (SGYP), Novavax (NVAX), Arena Pharmaceuticals (ARNA), Inovio Pharmaceuticals (INO), AVEO Pharmaceuticals (AVEO), Alibaba Group (BABA), Dynavax Technologies (DVAX), Amicus Therapeutics (FOLD) and Opko Health (OPK). Who are Anthera Pharmaceuticals' key executives? Anthera Pharmaceuticals' management team includes the following people: Mr. Paul F. Truex, Exec. Chairman (Age 49)Mr. John Craig Thompson, Pres, CEO & Director (Age 51)Dr. Renee Martin Ph.D., Sr. VP of Medical Sciences (Age 49)Dr. William R. Shanahan Jr., M.D., J.D., Chief Medical Officer & Sr. VP (Age 69)Ms. May Liu, Chief Accounting Officer, Sr. VP of Fin. & Admin. and Compliance Officer (Age 42) What is Anthera Pharmaceuticals' stock symbol? Anthera Pharmaceuticals trades on the OTCMKTS under the ticker symbol "ANTH." How do I buy shares of Anthera Pharmaceuticals? Shares of ANTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Anthera Pharmaceuticals' stock price today? One share of ANTH stock can currently be purchased for approximately $0.03. What is Anthera Pharmaceuticals' official website? The official website for Anthera Pharmaceuticals is www.anthera.com. How can I contact Anthera Pharmaceuticals? Anthera Pharmaceuticals' mailing address is 25801 INDUSTRIAL BOULEVARD SUITE B, HAYWARD CA, 94545. The biopharmaceutical company can be reached via phone at 510-856-5600. This page was last updated on 6/7/2020 by MarketBeat.com Staff
